From LSE NCYT
Focus should now switch to the "direct-to-PCR" extraction method
Fri 21:45
It's time for any serious investors to stop focusing (almost obsessing) on sales updates and read the last RNS again.
It is clear to me that the company is now being driven by manufacturing, not updating the market with every EUA, £1m+ order we receive. I think we can be safe in the knowledge that we are selling everything we make based on the fact we are looking to DOUBLE the number of tests from 4 to 8m whilst continuing to look for other third party manufacturers to yet further increase...!
Instead, I'd personally look to focus on the "direct-to-PCR" extraction method and the significance of this to the future of COVID19 testing, testing in the UK.
The first we heard of this new extraction methodology was in the previous RNS. Why is it important?
1. This removes the need for some scarce reagents
2. Significantly reduces the number of extraction steps
3. Allows for faster cycle times, higher throughputs and cost savings
What does Graham and the directors think of it?
"The Directors believe this innovation should facilitate an INCREASE IN TESTING CAPACITY for COVID-19, removing a current bottleneck in sample processing for laboratories."
Reading the above extract, I wouldn't be surprised if it includes GSK & AstraZeneca involvement to generate the national interest and help us scale up.
I also expect this to therefore be Government endorsed and expect a big push in the weeks ahead from the media and Matt Han**** etc, especially off the back of the recent news from the WHO that casts doubt over the reliability of AB tests.
Picture the first week of May, selling 8m tests per month and just about to launch a new extraction method for PCR testing with backing of key players and Government...
Sit back, hold your shares and enjoy the ride!